Article Text

Download PDFPDF
Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary
  1. Yasushi Umezaki, MD*,
  2. Masahiro Ito, MD*,
  3. Masahiro Nakashima, MD,
  4. Yumi Mihara, MD*,
  5. Hirokazu Kurohama, MD*,
  6. Naoko Yatsunami, MD and
  7. Ichiro Yasuhi, MD
  1. *Department of Pathology, National Hospital Organization Nagasaki Medical Center;
  2. Department of Tumour and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences; and
  3. Department of Obstetrics and Gynecology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.
  1. Address correspondence and reprint requests to Yasushi Umezaki, MD, National Hospital Organization Nagasaki Medical Center 2-1001-1 Kubara, Omura 856-0835, Nagasaki, Japan. E-mail: umezaki{at}nagasaki-mc.com.

Abstract

Objective The S100P protein stimulates cell proliferation and survival, thereby contributing to cancer progression. The purposes of this study were to evaluate S100P expression in ovarian clear cell adenocarcinoma and to determine whether S100P expression was correlated with the clinicopathological features or prognoses of patients with clear cell adenocarcinoma.

Methods We examined S100P expression in 30 ovarian clear cell adenocarcinoma specimens using immunohistochemistry analysis. The Kaplan-Meier method was used for analysis of overall survival, and comparisons were made based on the log-rank test.

Results Negative staining for nuclear S100P was associated with a poor prognosis as compared with that of positive staining for nuclear S100P in specimens from patients with clear cell adenocarcinoma.

Conclusions These data suggested that S100P may serve as an independent prognostic factor and marker for acquired resistance to chemotherapeutic drugs in clear cell adenocarcinoma.

  • Clear cell adenocarcinoma
  • Immunohistochemistry
  • Ovary
  • Prognosis
  • S100P

Statistics from Altmetric.com

Footnotes

  • This study has no sources of funding.

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.